Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

SML0816

Sigma-Aldrich

Pramiracetam

≥98% (HPLC)

Synonyme(s) :

Amacetam, N-[2-(Diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide, N-[2-[Bis(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide, Vinpotropil

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C14H27N3O2
Numéro CAS:
Poids moléculaire :
269.38
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Essai

≥98% (HPLC)

Forme

powder

Couleur

white to beige

Solubilité

H2O: 10 mg/mL, clear

Température de stockage

2-8°C

Chaîne SMILES 

[S](=O)(=O)([O-])O.[N+H](C(C)C)(C(C)C)CCNC(=O)CN1CCCC1=O

InChI

1S/C14H27N3O2.H2O4S/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19;1-5(2,3)4/h11-12H,5-10H2,1-4H3,(H,15,18);(H2,1,2,3,4)

Clé InChI

ACSROKXFXFNERX-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Pramiracetam is a potent nootropic agent that is a member of the racetam drug family. Pramiracetam improves cognitive deficits associated with traumatic brain injuries. Also, pramiracetam is a specific inhibitor of prolyl endopeptidase.
Pramiracetam is a potent nootropic agent.
Pramiracetam plays an important role in spatial learning and memory in rats. It is considered as a memory enhancing agent and is stronger than piracetam.

Caractéristiques et avantages

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Pictogrammes

Exclamation mark

Mention d'avertissement

Warning

Mentions de danger

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J J Claus et al.
Neurology, 41(4), 570-574 (1991-04-01)
The cognitive-enhancing effects of pramiracetam in animal models of learning and memory are characterized by an inverted U-shaped dose-response curve. We evaluated antidementia efficacy of this drug in 10 patients with probable Alzheimer's disease employing a 2-phase, placebo-controlled, enrichment-type trial
A J Gower et al.
Neuropharmacology, 25(10), 1161-1166 (1986-10-01)
Rats were tested for tail-flick responses and then immediately subjected to footshock for 30 sec. This procedure induced analgesia, i.e. prolonged the latency of the tail-flick response, which was maximal immediately after the shock and decayed to normal levels within
L A Dziak et al.
Likars'ka sprava, (8)(8), 67-72 (2004-02-18)
Morbidity rise of cerebrovascular pathology is followed by remarkable cognitive decline. Chronic cerebral blood insufficiency and stroke consequences compose a group of the diseases which lead to different types of memory deterioration, consecutive memory decline and as a result to
T Chang et al.
Journal of clinical pharmacology, 25(4), 291-295 (1985-05-01)
The pharmacokinetics of pramiracetam, a new, investigational, cognition activator, were assessed in normal male volunteers as part of a clinical tolerance study. In a double-blind, randomized design, two groups of six subjects each received alternating placebo and single 400, 800
A Auteri et al.
International journal of clinical pharmacology research, 12(3), 129-132 (1992-01-01)
The pharmacokinetics of pramiracetam was assessed using an HPLC method after oral administration of two different formulations of 600 mg (a solution and a tablet) of pramiracetam to 11 fasting volunteers. The mean kinetic parameters were: t1 = 4.7 +/-

Articles

DISCOVER Bioactive Small Molecules for Neuroscience

DISCOVER Bioactive Small Molecules for Neuroscience

DISCOVER Bioactive Small Molecules for Neuroscience

DISCOVER Bioactive Small Molecules for Neuroscience

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique